MX2009002859A - Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. - Google Patents

Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.

Info

Publication number: MX2009002859A
Authority: MX; Mexico
Prior art keywords: substituted; compound according; further characterized; independently; group
Prior art date: 2006-09-15

Application number

MX2009002859A

Other languages

English (en)

Spanish (es)

Inventor

Hong Zhao

Original Assignee

Enzon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-15

Filing date

2007-09-15

Publication date

2009-03-30

2007-09-15 Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc

2009-03-30 Publication of MX2009002859A publication Critical patent/MX2009002859A/es

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 107
150000002148 esters Chemical class 0.000 title claims abstract description 29
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 55
150000001875 compounds Chemical class 0.000 claims description 117
229920000642 polymer Polymers 0.000 claims description 71
229920001223 polyethylene glycol Polymers 0.000 claims description 54
239000002202 Polyethylene glycol Substances 0.000 claims description 43
125000000217 alkyl group Chemical group 0.000 claims description 35
238000000034 method Methods 0.000 claims description 34
125000004423 acyloxy group Chemical group 0.000 claims description 33
125000004404 heteroalkyl group Chemical group 0.000 claims description 28
-1 amino, substituted amino Chemical group 0.000 claims description 27
125000005647 linker group Chemical group 0.000 claims description 24
239000000074 antisense oligonucleotide Substances 0.000 claims description 23
238000012230 antisense oligonucleotides Methods 0.000 claims description 23
125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 23
125000003118 aryl group Chemical group 0.000 claims description 23
125000005129 aryl carbonyl group Chemical group 0.000 claims description 22
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 22
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 22
108091033319 polynucleotide Proteins 0.000 claims description 20
102000040430 polynucleotide Human genes 0.000 claims description 20
239000002157 polynucleotide Substances 0.000 claims description 20
125000001072 heteroaryl group Chemical group 0.000 claims description 18
125000002252 acyl group Chemical group 0.000 claims description 17
125000003545 alkoxy group Chemical group 0.000 claims description 17
229920000233 poly(alkylene oxides) Polymers 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 16
150000007523 nucleic acids Chemical class 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 15
239000001257 hydrogen Substances 0.000 claims description 15
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
229910052760 oxygen Inorganic materials 0.000 claims description 14
125000003107 substituted aryl group Chemical group 0.000 claims description 14
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 14
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
125000004405 heteroalkoxy group Chemical group 0.000 claims description 13
102000039446 nucleic acids Human genes 0.000 claims description 13
108020004707 nucleic acids Proteins 0.000 claims description 13
229910052717 sulfur Inorganic materials 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
230000001588 bifunctional effect Effects 0.000 claims description 12
230000000890 antigenic effect Effects 0.000 claims description 11
125000004104 aryloxy group Chemical group 0.000 claims description 11
230000000903 blocking effect Effects 0.000 claims description 11
125000005553 heteroaryloxy group Chemical group 0.000 claims description 11
229920001427 mPEG Polymers 0.000 claims description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
108020004414 DNA Proteins 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 10
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
125000003729 nucleotide group Chemical group 0.000 claims description 9
125000005017 substituted alkenyl group Chemical group 0.000 claims description 9
125000000547 substituted alkyl group Chemical group 0.000 claims description 9
108020004459 Small interfering RNA Proteins 0.000 claims description 8
125000004429 atom Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
239000004055 small Interfering RNA Substances 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 7
239000002773 nucleotide Substances 0.000 claims description 7
125000004426 substituted alkynyl group Chemical group 0.000 claims description 7
102000053642 Catalytic RNA Human genes 0.000 claims description 6
108090000994 Catalytic RNA Proteins 0.000 claims description 6
108091030071 RNAI Proteins 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
239000003574 free electron Substances 0.000 claims description 6
230000009368 gene silencing by RNA Effects 0.000 claims description 6
108091092562 ribozyme Proteins 0.000 claims description 6
125000004414 alkyl thio group Chemical group 0.000 claims description 5
239000000032 diagnostic agent Substances 0.000 claims description 5
229940039227 diagnostic agent Drugs 0.000 claims description 5
229930195733 hydrocarbon Natural products 0.000 claims description 5
150000002430 hydrocarbons Chemical class 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 claims description 4
108091023037 Aptamer Proteins 0.000 claims description 4
239000004215 Carbon black (E152) Substances 0.000 claims description 4
102000053602 DNA Human genes 0.000 claims description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
108700011259 MicroRNAs Proteins 0.000 claims description 4
108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
230000002209 hydrophobic effect Effects 0.000 claims description 4
239000002679 microRNA Substances 0.000 claims description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
229920001451 polypropylene glycol Polymers 0.000 claims description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
229920003169 water-soluble polymer Polymers 0.000 claims description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
239000012948 isocyanate Substances 0.000 claims description 3
150000002513 isocyanates Chemical class 0.000 claims description 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 2
WROTXLSEMHAZEA-UHFFFAOYSA-N 4-diaminophosphoryloxymorpholine Chemical compound NP(N)(=O)ON1CCOCC1 WROTXLSEMHAZEA-UHFFFAOYSA-N 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
150000003862 amino acid derivatives Chemical class 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
230000009401 metastasis Effects 0.000 claims description 2
230000001613 neoplastic effect Effects 0.000 claims description 2
KITHNHJPIHPBQH-UHFFFAOYSA-N nitro(nitrosilyloxy)silane Chemical compound [N+](=O)([O-])[SiH2]O[SiH2][N+](=O)[O-] KITHNHJPIHPBQH-UHFFFAOYSA-N 0.000 claims description 2
229920002477 rna polymer Polymers 0.000 claims description 2
125000001589 carboacyl group Chemical group 0.000 claims 8
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
230000008685 targeting Effects 0.000 claims 1
238000001727 in vivo Methods 0.000 abstract description 10
238000004519 manufacturing process Methods 0.000 abstract description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
239000002585 base Substances 0.000 description 25
239000000047 product Substances 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 19
210000004027 cell Anatomy 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
230000000692 anti-sense effect Effects 0.000 description 15
239000000243 solution Substances 0.000 description 15
238000002360 preparation method Methods 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
230000027455 binding Effects 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
108020000948 Antisense Oligonucleotides Proteins 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
230000014509 gene expression Effects 0.000 description 9
229940046166 oligodeoxynucleotide Drugs 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
230000000670 limiting effect Effects 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000007062 hydrolysis Effects 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 6
229960000435 oblimersen Drugs 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
239000002904 solvent Substances 0.000 description 6
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
108010002687 Survivin Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
125000003396 thiol group Chemical group [H]S* 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
210000004881 tumor cell Anatomy 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
238000011160 research Methods 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
108010077895 Sarcosine Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
239000007822 coupling agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000003301 hydrolyzing effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
238000001308 synthesis method Methods 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical class C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101150017888 Bcl2 gene Proteins 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 2
102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000012043 crude product Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000011033 desalting Methods 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000000178 monomer Substances 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
150000008300 phosphoramidites Chemical class 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
229940043230 sarcosine Drugs 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
KLRAVUCDVJAWKB-UHFFFAOYSA-N (6-carboxy-6-methylheptyl)-diazonioazanide Chemical compound OC(=O)C(C)(C)CCCCCN=[N+]=[N-] KLRAVUCDVJAWKB-UHFFFAOYSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
ABVLHCHEPLLSCH-LPMNBDSKSA-N 1-[(2r,4s,5r)-4-acetyl-5-(8-amino-1-hydroxy-3,3-dimethyl-2-oxooctyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O1[C@H](C(O)C(=O)C(C)(C)CCCCCN)[C@@](C(=O)C)(O)C[C@@H]1N1C(=O)NC(=O)C(C)=C1 ABVLHCHEPLLSCH-LPMNBDSKSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
HAWJUUUDZFZUKG-UHFFFAOYSA-N 2,2-diaminoheptanedioic acid Chemical compound OC(=O)C(N)(N)CCCCC(O)=O HAWJUUUDZFZUKG-UHFFFAOYSA-N 0.000 description 1
TWMVVJUXUMIAAJ-UHFFFAOYSA-N 2,2-dimethyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(C)(C)C(O)=O TWMVVJUXUMIAAJ-UHFFFAOYSA-N 0.000 description 1
PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
JCCCMAAJYSNBPR-UHFFFAOYSA-N 2-ethylthiophene Chemical compound CCC1=CC=CS1 JCCCMAAJYSNBPR-UHFFFAOYSA-N 0.000 description 1
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 1
ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
PQVHMOLNSYFXIJ-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazole-3-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(N1CC2=C(CC1)NN=N2)=O)C(=O)O PQVHMOLNSYFXIJ-UHFFFAOYSA-N 0.000 description 1
ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108091012583 BCL2 Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
WCDLURSQJUSFJE-LPMNBDSKSA-N CC(=O)[C@]1(O)C[C@@H](O[C@@H]1C(O)C(=O)C(C)(C)CCCCCN=[N+]=[N-])n1cc(C)c(=O)[nH]c1=O Chemical compound CC(=O)[C@]1(O)C[C@@H](O[C@@H]1C(O)C(=O)C(C)(C)CCCCCN=[N+]=[N-])n1cc(C)c(=O)[nH]c1=O WCDLURSQJUSFJE-LPMNBDSKSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000776457 FCB group Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
OLNLSTNFRUFTLM-BYPYZUCNSA-N N-ethyl-L-asparagine Chemical compound CCN[C@H](C(O)=O)CC(N)=O OLNLSTNFRUFTLM-BYPYZUCNSA-N 0.000 description 1
YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
108010065338 N-ethylglycine Proteins 0.000 description 1
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101000585507 Solanum tuberosum Cytochrome b-c1 complex subunit 7 Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
229910010277 boron hydride Inorganic materials 0.000 description 1
239000012267 brine Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical compound O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
HIFNBAJFEAXDGZ-UHFFFAOYSA-N diazonio-(7-ethoxy-6,6-dimethyl-7-oxoheptyl)azanide Chemical compound CCOC(=O)C(C)(C)CCCCCN=[N+]=[N-] HIFNBAJFEAXDGZ-UHFFFAOYSA-N 0.000 description 1
TXFOLHZMICYNRM-UHFFFAOYSA-N dichlorophosphoryloxybenzene Chemical class ClP(Cl)(=O)OC1=CC=CC=C1 TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000002641 enzyme replacement therapy Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
SYRIIFZUZOIRNU-UHFFFAOYSA-N ethyl 7-bromo-2,2-dimethylheptanoate Chemical compound CCOC(=O)C(C)(C)CCCCCBr SYRIIFZUZOIRNU-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000006870 function Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
125000005358 mercaptoalkyl group Chemical group 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
229940000673 orphan drug Drugs 0.000 description 1
239000002859 orphan drug Substances 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
GTCDARUMAMVCRO-UHFFFAOYSA-M tetraethylazanium;acetate Chemical compound CC([O-])=O.CC[N+](CC)(CC)CC GTCDARUMAMVCRO-UHFFFAOYSA-M 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
125000005425 toluyl group Chemical group 0.000 description 1
AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Environmental Sciences (AREA)
Pest Control & Pesticides (AREA)
Microbiology (AREA)
Dentistry (AREA)
Agronomy & Crop Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2009002859A 2006-09-15 2007-09-15 Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. MX2009002859A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84502806P	2006-09-15	2006-09-15
PCT/US2007/078597 WO2008034122A2 (fr)	2006-09-15	2007-09-15	Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides

Publications (1)

Publication Number	Publication Date
MX2009002859A true MX2009002859A (es)	2009-03-30

Family

ID=39184642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2009002859A MX2009002859A (es)	2006-09-15	2007-09-15	Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.

Country Status (9)

Country	Link
EP (1)	EP2063709A2 (fr)
JP (1)	JP2010503707A (fr)
KR (1)	KR20090055623A (fr)
CN (1)	CN101534643A (fr)
AU (1)	AU2007296054B2 (fr)
CA (1)	CA2662978A1 (fr)
IL (1)	IL197516A0 (fr)
MX (1)	MX2009002859A (fr)
WO (1)	WO2008034122A2 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2569558T3 (es)	2006-04-03	2016-05-11	Roche Innovation Center Copenhagen A/S	Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
MX2008012219A (es)	2006-04-03	2008-10-02	Santaris Pharma As	Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
EP2063912A4 (fr) *	2006-09-15	2010-07-28	Enzon Pharmaceuticals Inc	Polyalkylène oxydes présentant des segments de liaison biodégradables à base d'ester encombré
US20100279408A1 (en) *	2006-11-27	2010-11-04	Enzon Pharmaceuticals, Inc.	Polymeric short interfering rna conjugates
WO2008113832A2 (fr)	2007-03-22	2008-09-25	Santaris Pharma A/S	Composés arn antagonistes courts pour la modulation de l'arnm cible
US8470791B2 (en)	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2008132234A2 (fr)	2007-05-01	2008-11-06	Santaris Pharma A/S	Composés antagonistes de l'arn pour la modulation de la béta caténine
AU2008250033A1 (en)	2007-05-11	2008-11-20	Enzon Pharmaceuticals, Inc.	RNA antagonist compounds for the modulation of HER3
KR20100072185A (ko)	2007-09-24	2010-06-30	녹손 파르마 아게	씨파이브에이 결합형 핵산
AU2008306327B2 (en)	2007-10-04	2014-05-15	Roche Innovation Center Copenhagen A/S	Micromirs
US8450290B2 (en)	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
EP2225377B1 (fr)	2007-11-26	2014-01-08	Santaris Pharma A/S	Antagonistes basés sur les lna ciblant le récepteur de l'androgène
TW200927176A (en)	2007-12-03	2009-07-01	Santaris Pharma As	RNA antagonist compounds for the modulation of PIK3CA expression
US8404659B2 (en)	2008-03-07	2013-03-26	Santaris Pharma A/S	Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (es)	2008-08-01	2015-07-20	Roche Innovation Center Copenhagen A/S	Modulación mediada por microARN de factores estimulantes de colonias
DK2328619T3 (en) *	2008-08-22	2017-03-13	Baxalta GmbH	POLYMER BENZYL CARBONATE DERIVATES
US20120065254A1 (en)	2009-03-23	2012-03-15	Noxxon Pharma Ag	C5A binding nucleic acids and the use thereof
WO2010122538A1 (fr)	2009-04-24	2010-10-28	Santaris Pharma A/S	Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons
CN102802637A (zh)	2009-06-12	2012-11-28	桑塔里斯制药公司	新的有力的抗apob反义化合物
EP2456870A1 (fr)	2009-07-21	2012-05-30	Santaris Pharma A/S	Oligomères anti-sens ciblant pcsk9
UA108475C2 (uk)	2009-07-31	2015-05-12	Санофі-Авентіс Дойчланд Гмбх	Композиція інсуліну тривалої дії
KR20120089843A (ko)	2009-07-31	2012-08-14	사노피-아벤티스 도이칠란트 게엠베하	인슐린 링커 접합체를 포함한 프로드럭
LT2459220T (lt)	2009-07-31	2020-12-28	Ascendis Pharma A/S	Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US9364495B2 (en)	2009-10-20	2016-06-14	Roche Innovation Center Copenhagen A/S	Oral delivery of therapeutically effective LNA oligonucleotides
WO2011054811A1 (fr)	2009-11-03	2011-05-12	Santaris Pharma A/S	Traitement combiné par des antagonistes d'arn ciblant hsp-27
JP5941904B2 (ja)	2010-04-21	2016-06-29	ノクソンファーマエージー	脂質に結合する核酸
WO2012007477A1 (fr)	2010-07-12	2012-01-19	Santaris Pharma A/S	Oligomères anti-vhc
WO2012025251A1 (fr)	2010-08-27	2012-03-01	Noxxon Pharma Ag	Acides nucléiques destinés au traitement de complications chroniques du diabète
US20130310442A1 (en)	2010-09-09	2013-11-21	Noxxon Pharma Ag	SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
WO2012034942A1 (fr)	2010-09-13	2012-03-22	Santaris Pharma A/S	Composés pour la modulation de l'expression de la kinase aurora b
EP2438930A1 (fr)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Promédicaments comprenant un conjugué de liaison d'exendine
EP2633053A1 (fr)	2010-10-29	2013-09-04	Noxxon Pharma AG	Utilisation d'acides nucléiques capables de se lier à l'hepcidine afin d'entraîner une diminution du niveau d'hepcidine dans l'organisme
AU2011326034B2 (en)	2010-11-12	2016-02-04	Roche Innovation Center Copenhagen A/S	Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012066093A1 (fr)	2010-11-19	2012-05-24	Santaris Pharma A/S	Composés pour la modulation de l'expression de la protéine kinase pbk à liaison avec pdz
WO2012066092A1 (fr)	2010-11-19	2012-05-24	Santaris Pharma A/S	Composés de modulation de l'expression de l'aurora kinase a
AU2012206750A1 (en)	2011-01-10	2013-07-18	Noxxon Pharma Ag	Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2012110457A2 (fr)	2011-02-14	2012-08-23	Santaris Pharma A/S	Composés pour la modulation de l'expression de l'ostéopontine
WO2012143427A1 (fr)	2011-04-19	2012-10-26	Santaris Pharma A/S	Composés anti-polyomavirus
US20140127159A1 (en)	2011-06-23	2014-05-08	Stella Aps	HCV Combination Therapy
KR20140058536A (ko)	2011-06-30	2014-05-14	스텔라 에이피에스	Hcv 조합 치료
EP2726610A1 (fr)	2011-06-30	2014-05-07	Stella ApS	Polythérapie anti-vhc
PT2581448E (pt) *	2011-10-13	2015-05-21	Institut National De La Santé Et De La Rech Médicale (Inserm)	Dna triciclo-fosforotioato
BR112014009104A2 (pt)	2011-10-21	2017-04-18	Noxxon Pharma Ag	ácidos nucleicos que se ligam ao glucagon
ES2607681T3 (es)	2011-11-07	2017-04-03	Roche Innovation Center Copenhagen A/S	Método de pronóstico para comprobar la eficacia de inhibidores de micro ARN-122 en pacientes VHC+
CA2855241A1 (fr)	2011-11-11	2013-05-16	Santaris Pharma A/S	Composes pour la modulation de l'epissage de smn2
MX2014008456A (es)	2012-01-10	2014-11-25	Noxxon Pharma Ag	Acidos nucleicos que enlazan especificamente a cgrp.
DK2802660T3 (da)	2012-01-10	2020-05-18	Aptarion Biotech Ag	Nye C5A-bindende nucleinsyrer
RU2704833C2 (ru)	2012-05-16	2019-10-31	Аптарион Биотек Аг	Ферментативный синтез l-нуклеиновых кислот
CA2889044A1 (fr)	2012-11-15	2014-05-22	Roche Innovation Center Copenhagen A/S	Composes conjugues antisens anti-apob
WO2014080004A1 (fr)	2012-11-26	2014-05-30	Santaris Pharma A/S	Compositions et méthodes pour la modulation de l'expression de fgfr3
MX391977B (es)	2013-06-27	2025-03-21	Roche Innovation Ct Copenhagen As	Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
JP2017502075A (ja)	2013-11-04	2017-01-19	ノクソンファーマエージー	腎障害治療の手段および方法
GB201408623D0 (en)	2014-05-15	2014-07-02	Santaris Pharma As	Oligomers and oligomer conjugates
GB201414098D0 (en) *	2014-08-08	2014-09-24	Illumina Cambridge Ltd	Modified nucleotide linkers
US10815481B2 (en)	2014-12-16	2020-10-27	Roche Innovation Center Copenhagen A/S	Chiral library screen
WO2017118704A1 (fr)	2016-01-08	2017-07-13	Ascendis Pharma Growth Disorders A/S	Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c
CA3008017C (fr)	2016-01-08	2024-01-02	Ascendis Pharma Growth Disorders A/S	Agonistes de cnp a liberation controlee presentant des effets secondaires reduits
WO2017118693A1 (fr)	2016-01-08	2017-07-13	Ascendis Pharma Growth Disorders A/S	Promédicaments du cnp possédant de grands fragments à rôle de transporteur
SMT202200466T1 (it)	2016-01-08	2023-01-13	Ascendis Pharma Growth Disorders As	Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
EP3400022A1 (fr)	2016-01-08	2018-11-14	Ascendis Pharma Growth Disorders A/S	Agonistes de cnp à libération contrôlée avec faible activité npr-b initiale
NZ743487A (en)	2016-01-08	2023-02-24	Ascendis Pharma Growth Disorders As	Controlled-release cnp agonists with increased nep stability
SMT202400423T1 (it)	2016-03-01	2024-11-15	Ascendis Pharma Bone Diseases As	Profarmaci di pth
WO2017178119A1 (fr)	2016-04-15	2017-10-19	Noxxon Pharma Ag	Procédé de modulation du nombre et de la répartition des leucocytes infiltrant les tumeurs dans les tumeurs
SG11201809468XA (en)	2016-04-29	2018-11-29	Sarepta Therapeutics Inc	Oligonucleotide analogues targeting human lmna
CA3030376A1 (fr)	2016-07-13	2018-01-18	Ascendis Pharma A/S	Procede de conjugaison pour promedicaments lies a un support
RS64440B1 (sr)	2016-09-29	2023-09-29	Ascendis Pharma Bone Diseases As	Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
NZ792622A (en)	2016-09-29	2025-08-29	Ascendis Pharma Bone Diseases As	Pth compounds with low peak-to-trough ratios
PT3518982T (pt)	2016-09-29	2025-01-29	Ascendis Pharma Bone Diseases As	Descoberta da dose incremental em compostos de pth de libertação controlada
IL321464A (en)	2016-09-29	2025-08-01	Ascendis Pharma Growth Disorders As	Combination therapy with controlled-release cnp agonists
AU2018240375C1 (en)	2017-03-22	2024-02-01	Ascendis Pharma A/S	Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
KR102141124B1 (ko)	2018-01-30	2020-08-04	(주)바이오니아	이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도
MA52662A (fr)	2018-03-28	2021-02-17	Ascendis Pharma Oncology Div A/S	Conjugués d'il-2
CA3093083A1 (fr)	2018-03-28	2019-10-03	Ascendis Pharma A/S	Conjugues
DK3793587T3 (da)	2018-05-18	2025-07-21	Ascendis Pharma Bone Diseases As	Startdosis af pth-konjugater
US20210220387A1 (en)	2018-05-18	2021-07-22	Hoffmann-La Roche, Inc.	Pharmaceutical compositions for treatment of microrna related diseases
WO2020064847A1 (fr)	2018-09-26	2020-04-02	Ascendis Pharma A/S	Hydrogels dégradables d'acide hyaluronique
EP3856255A1 (fr)	2018-09-26	2021-08-04	Ascendis Pharma A/S	Traitement d'infections
EP3856256A1 (fr)	2018-09-26	2021-08-04	Ascendis Pharma A/S	Nouveaux conjugués d'hydrogel
US20220054476A1 (en)	2019-01-04	2022-02-24	Ascendis Pharma Oncology Division A/S	Sustained local drug levels for innate immune agonists
BR112021011592A2 (pt)	2019-01-04	2021-10-26	Ascendis Pharma Oncology Division A/S	Conjugados de agonistas de receptor de reconhecimento de padrão
WO2020141223A1 (fr)	2019-01-04	2020-07-09	Ascendis Pharma A/S	Induction d'une inflammation locale soutenue
CA3125541A1 (fr)	2019-01-04	2020-07-09	Ascendis Pharma Oncology Division A/S	Minimisation de l'inflammation systemique
EP3923905A1 (fr)	2019-02-11	2021-12-22	Ascendis Pharma Bone Diseases A/S	Formulations pharmaceutiques liquides de conjugués pth
US12377133B2 (en)	2019-02-11	2025-08-05	Ascendis Pharma Growth Disorders A/S	Dry pharmaceutical formulations of CNP conjugates
WO2020254612A1 (fr)	2019-06-21	2020-12-24	Ascendis Pharma Oncology Division A/S	Composés inhibiteurs de tyrosine kinases à libération contrôlée présentant des propriétés pharmacodynamiques localisées
EP3986478A1 (fr)	2019-06-21	2022-04-27	Ascendis Pharma Oncology Division A/S	Conjugués inhibiteur de tyrosine kinase
WO2020254613A1 (fr)	2019-06-21	2020-12-24	Ascendis Pharma Oncology Division A/S	Composés inhibiteurs de tyrosine kinase à libération contrôlée présentant des propriétés pharmacocinétiques localisées
WO2020254607A1 (fr)	2019-06-21	2020-12-24	Ascendis Pharma Oncology Division A/S	Composés anti-ctla4 à propriétés pd localisées
AU2020295725A1 (en)	2019-06-21	2021-12-02	Ascendis Pharma Oncology Division A/S	Anti-CTLA4 conjugates
WO2020254617A1 (fr)	2019-06-21	2020-12-24	Ascendis Pharma Oncology Division A/S	Composés anti-ctla4 présentant des propriétés pharmacocinétiques localisées
IL294357A (en)	2020-01-13	2022-08-01	Ascendis Pharma Bone Diseases As	Hypoparathyroidism treatment
WO2021224169A1 (fr)	2020-05-04	2021-11-11	Ascendis Pharma A/S	Irradiation d'hydrogel
JP2023527919A (ja)	2020-06-03	2023-06-30	アセンディスファーマオンコロジーディヴィジョンエー／エス	Ｉｌ－２配列及びその使用
TW202219060A (zh)	2020-08-28	2022-05-16	丹麥商阿森迪斯腫瘤製藥有限公司	醣基化il-2蛋白及其用途
CN112047840A (zh) *	2020-08-31	2020-12-08	山东药品食品职业学院	一种7-溴-2,2-二甲基庚酸乙酯的合成方法及合成得到的产品
IL301411A (en)	2020-09-28	2023-05-01	Ascendis Pharma Bone Diseases As	Improvement of physical and mental well-being of patients with hypoparathyroidism
MX2023011059A (es)	2021-04-01	2023-09-29	Ascendis Pharma As	Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
WO2022230990A1 (fr) *	2021-04-28	2022-11-03	国立研究開発法人科学技術振興機構	Acide nucléique artificiel et procédé d'administration d'acide nucléique l'utilisant
WO2023046732A1 (fr)	2021-09-22	2023-03-30	Ascendis Pharma Bone Diseases A/S	Traitements avec des composés pth à action prolongée
AU2022409306A1 (en)	2021-12-13	2024-06-06	Ascendis Pharma Oncology Division A/S	Cancer treatments with tlr7/8 agonists
WO2023110758A1 (fr)	2021-12-13	2023-06-22	Ascendis Pharma Growth Disorders A/S	Doses efficaces de conjugués cnp
JP2025522281A (ja)	2022-05-23	2025-07-15	アセンディスファーマグロースディスオーダーズエー／エス	Ｃｎｐ化合物の液体医薬製剤
EP4306640A1 (fr)	2022-06-21	2024-01-17	TME Pharma AG	Procédé de traitement d'une tumeur chez un sujet
KR20250025627A (ko)	2022-06-21	2025-02-24	티엠이 파마 아게	대상체의 종양을 치료하는 방법
AU2023374533A1 (en)	2022-11-02	2025-04-10	Ascendis Pharma Bone Diseases A/S	Pth treatment regimen comprising two pth compounds
WO2024104922A1 (fr)	2022-11-14	2024-05-23	Ascendis Pharma Growth Disorders A/S	Procédé d'amélioration de la fonction musculaire squelettique
TW202434299A (zh)	2023-01-05	2024-09-01	丹麥商阿仙帝斯製藥公司	製造水凝膠微球之方法
TW202430223A (zh)	2023-01-05	2024-08-01	丹麥商阿仙帝斯眼科製藥有限公司	用於治療眼部病症之藥物結合物
WO2024184352A1 (fr)	2023-03-06	2024-09-12	Ascendis Pharma A/S	Composés médicamenteux comprenant des fractions de liaison à l'albumine
TW202440150A (zh)	2023-03-06	2024-10-16	丹麥商阿仙帝斯製藥公司	具白蛋白結合部分之藥物化合物
WO2024184354A1 (fr)	2023-03-06	2024-09-12	Ascendis Pharma A/S	Composés de liaison à plusieurs albumines
AU2024240722A1 (en)	2023-03-20	2025-09-18	Ascendis Pharma Growth Disorders A/S	Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
AU2024270185A1 (en)	2023-05-09	2025-11-06	Ascendis Pharma Oncology Division A/S	Novel cancer treatments with il-2 conjugates
WO2025051711A1 (fr)	2023-09-04	2025-03-13	Ascendis Pharma Bone Diseases A/S	Traitement par pth d'une maladie rénale chronique
WO2025196240A1 (fr)	2024-03-20	2025-09-25	Aptarion Biotech Ag	Méthode de traitement d'un trouble avec un inhibiteur de c5a
EP4620474A1 (fr)	2024-03-20	2025-09-24	APTARION biotech AG	Procédé de traitement d'un trouble avec un inhibiteur de c5a

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904582A (en) *	1987-06-11	1990-02-27	Synthetic Genetics	Novel amphiphilic nucleic acid conjugates
US5606045A (en) *	1990-05-15	1997-02-25	Diatron Corporation	Nucleic acid probes and methods
JP2002510319A (ja) *	1997-07-01	2002-04-02	アイシス・ファーマシューティカルス・インコーポレーテッド	オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
EP1037649B1 (fr) *	1997-12-17	2009-09-30	Enzon, Inc.	Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US5965119A (en) *	1997-12-30	1999-10-12	Enzon, Inc.	Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ATE268609T1 (de) *	1998-03-12	2004-06-15	Nektar Therapeutics Al Corp	Polyethylenglycolderivate mit benachbarten reaktiven gruppen
JP3485023B2 (ja) *	1999-05-20	2004-01-13	東亞合成株式会社	ヌクレオシド化合物
CA2382202A1 (fr) *	1999-08-26	2001-03-01	Sydney Brenner	Conjugues de medicaments et leurs procedes de preparation
KR100406739B1 (ko) *	2000-04-15	2003-11-20	주식회사 코오롱	파클리탁셀 또는 이의 유도체의 잔기를 포함하는 수용성프로드럭 화합물, 그의 제조 방법 및 그를 포함하는 약제조성물
WO2002043663A2 (fr) *	2000-12-01	2002-06-06	Enzon, Inc.	Promedicaments tetrapartates
US7332164B2 (en) *	2003-03-21	2008-02-19	Enzon Pharmaceuticals, Inc.	Heterobifunctional polymeric bioconjugates
KR20060015505A (ko) *	2003-04-13	2006-02-17	엔존 파마슈티컬즈, 인코포레이티드	올리고뉴클레오타이드 전구약물
EP2063912A4 (fr) *	2006-09-15	2010-07-28	Enzon Pharmaceuticals Inc	Polyalkylène oxydes présentant des segments de liaison biodégradables à base d'ester encombré

2007
- 2007-09-15 MX MX2009002859A patent/MX2009002859A/es not_active Application Discontinuation
- 2007-09-15 KR KR1020097007157A patent/KR20090055623A/ko not_active Withdrawn
- 2007-09-15 EP EP07842576A patent/EP2063709A2/fr not_active Withdrawn
- 2007-09-15 CA CA002662978A patent/CA2662978A1/fr not_active Abandoned
- 2007-09-15 AU AU2007296054A patent/AU2007296054B2/en not_active Ceased
- 2007-09-15 CN CNA2007800419367A patent/CN101534643A/zh active Pending
- 2007-09-15 WO PCT/US2007/078597 patent/WO2008034122A2/fr not_active Ceased
- 2007-09-15 JP JP2009528517A patent/JP2010503707A/ja active Pending
2009
- 2009-03-10 IL IL197516A patent/IL197516A0/en unknown

Also Published As

Publication number	Publication date
JP2010503707A (ja)	2010-02-04
AU2007296054A1 (en)	2008-03-20
AU2007296054B2 (en)	2013-03-28
WO2008034122A3 (fr)	2008-10-30
CN101534643A (zh)	2009-09-16
EP2063709A2 (fr)	2009-06-03
CA2662978A1 (fr)	2008-03-20
WO2008034122A2 (fr)	2008-03-20
IL197516A0 (en)	2009-12-24
KR20090055623A (ko)	2009-06-02

Publication	Publication Date	Title
MX2009002859A (es)	2009-03-30	Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
US5965566A (en)	1999-10-12	High molecular weight polymer-based prodrugs
AU730244B2 (en)	2001-03-01	High molecular weight polymer-based prodrugs
Yang et al.	2003	Penicillin V-conjugated PEG-PAMAM star polymers
CN101534861B (zh)	2013-10-02	具有基于位阻酯的生物可降解连接基的聚环氧烷
JP2011520983A (ja)	2011-07-21	オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
US20090203706A1 (en)	2009-08-13	Lysine-based polymeric linkers
CN101273051A (zh)	2008-09-24	聚合寡核苷酸前体药物
KR20100051722A (ko)	2010-05-17	피리딜 이황화 부분을 포함하는 폴리머 링커
MX2009002856A (es)	2009-03-30	Conjugados polimericos que contienen porciones cargadas positivamente.
WO2008070477A9 (fr)	2008-07-24	Conjugués d'arn à interférence courte polymères
US20080064863A1 (en)	2008-03-13	Conjugate of Peo and Double Stranded Nucleic Acid
US8110559B2 (en)	2012-02-07	Hindered ester-based biodegradable linkers for oligonucleotide delivery
CN101516362A (zh)	2009-08-26	含有带正电荷部分的聚合物的缀合物

Legal Events

Date	Code	Title	Description
2016-10-31	FA	Abandonment or withdrawal